With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market.

Growing investment in target diagnosis of cardiovascular disorders, TB and diabetes drives demand for clinical laboratory testing. Clinical lab tests help in diagnosing mellitus diabetes. According to the International Diabetes Federation article published in 2019, some 463 million adults were diabetic, and it is estimated that it will reach 700 million worldwide by 2045.